Sign Out
Primary Hypercholesterolemia: Ezetrol administered with an HMG-CoA reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B and TG and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia.
Administered in combination with fenofibrate as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B and non-HDL-C in patients with mixed hyperlipidemia.
Homozygous Familial Hypercholesterolemia (HoFH): Ezetrol administered with a statin for the reduction of elevated total-C and LDL-C levels in patients with HoFH. Patients may also receive adjunctive treatments (eg, LDL apheresis).
